ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 161 filers reported holding ESPERION THERAPEUTICS INC NE in Q2 2018. The put-call ratio across all filers is 3.67 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $224,000 | +0.9% | 4,874 | -2.5% | 0.00% | 0.0% |
| Q3 2018 | $222,000 | +31.4% | 4,999 | +16.1% | 0.00% | +50.0% |
| Q2 2018 | $169,000 | -45.7% | 4,304 | 0.0% | 0.00% | -60.0% |
| Q1 2018 | $311,000 | +6.5% | 4,304 | -2.9% | 0.01% | +25.0% |
| Q4 2017 | $292,000 | +16.3% | 4,433 | -11.6% | 0.00% | 0.0% |
| Q3 2017 | $251,000 | +27.4% | 5,012 | +18.0% | 0.00% | +33.3% |
| Q2 2017 | $197,000 | +21.6% | 4,247 | -7.7% | 0.00% | 0.0% |
| Q1 2017 | $162,000 | -38.4% | 4,600 | -75.8% | 0.00% | -40.0% |
| Q3 2016 | $263,000 | +39.9% | 19,000 | 0.0% | 0.01% | +25.0% |
| Q2 2016 | $188,000 | -41.4% | 19,000 | 0.0% | 0.00% | -33.3% |
| Q1 2016 | $321,000 | -24.1% | 19,000 | 0.0% | 0.01% | -14.3% |
| Q4 2015 | $423,000 | +122.6% | 19,000 | +136.3% | 0.01% | +133.3% |
| Q3 2015 | $190,000 | -85.3% | 8,040 | -49.1% | 0.00% | -66.7% |
| Q2 2015 | $1,292,000 | – | 15,800 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 3,791,300 | $3,715,474 | 4.82% |
| Two Seas Capital LP | 7,672,170 | $7,518,727 | 1.51% |
| Parkman Healthcare Partners LLC | 1,997,071 | $1,957,130 | 0.36% |
| Monaco Asset Management SAM | 1,171,779 | $1,148,343 | 0.34% |
| TANG CAPITAL MANAGEMENT LLC | 1,850,000 | $1,813,000 | 0.26% |
| Ikarian Capital, LLC | 1,737,636 | $1,702,883 | 0.20% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 3,189,517 | $3,125,727 | 0.12% |
| GSA CAPITAL PARTNERS LLP | 1,116,655 | $1,094 | 0.09% |
| XTX Topco Ltd | 519,129 | $508,746 | 0.09% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 60,000 | $58,800 | 0.08% |